| Enterome–SEVERAL: investment, 202006 financing round Series E €na with existing plus new investors SymBiosis LLC + Takeda Pharma |
2020-06-25 |
| Enterome–SymBiosis LLC: investment, 202006 financing round Series E €na incl new investor SymBiosis LLC |
2020-06-25 |
| Enterome–Takeda: investment, 202006 financing round Series E €na incl new investor Takeda Pharmaceutical Co Ltd |
2020-06-25 |
| RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion |
2020-06-22 |
| Royalty Pharma–SEVERAL: investment, 202006 IPO $2.175b+$326m with 60m+17.7m+11.65m Class A ordinary shares at $28/share at Nasdaq Global Select Market |
2020-06-18 |
| DiogenX–Juvenile Diabetes Research Foundation: investment, 202006 seed financing round totalling €4.5m incl investor JDRF T1D Fund |
2020-06-16 |
| DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund |
2020-06-16 |
| eTheRNA–Novalis LifeSciences: investment, 202006 financing round Series B totalling €34m incl new investor Novalis LifeSciences LLC |
2020-06-16 |
| eTheRNA–Omega Funds: investment, 202006 financing round Series B totalling €34m incl existing investor Omega Funds |
2020-06-16 |
| eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors |
2020-06-16 |
| GSK–Ideaya Biosciences: synthetic lethality, 202006– collab strategic partnership ww $100m upfront + milestones + royalties |
2020-06-16 |
| Ideaya Biosciences–GSK: investment, 202006 direct private placement $20m common stock purchase by GSK |
2020-06-16 |
| Bit Bio–ARCH Venture: investment, 202006 financing round Series A totalling $41.5m incl co-investor Arch Venture Partners |
2020-06-13 |
| Bit Bio–Foresite Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor Foresite Capital |
2020-06-13 |
| Bit Bio–Mission Group: public relations, 202006 service existent by April Six |
2020-06-13 |
| Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Bob Nelsen |
2020-06-13 |
| Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Jim Tananbaum |
2020-06-13 |
| Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Rick Klaunser |
2020-06-13 |
| Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum |
2020-06-13 |
| JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV |
2020-06-12 |
| Lexent Bio–Roche: investment, 202006 acquisition of Lexent Bio by Foundation Medicine |
2020-06-12 |
| Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk |
2020-06-11 |
| Corvidia Therapeutics–McDougall Communications: public relations, 202006 service existent by McDougall |
2020-06-11 |
| Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED |
2020-06-11 |
| Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics |
2020-06-11 |
| 10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research |
2020-06-10 |
| Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investorj JnJ Innovation |
2020-06-10 |
| Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al |
2020-06-10 |
| Protera–SEVERAL: investment, 202006 financing round Series A $5.6m led by Sofinnova Partners + incl existing investor SOSV |
2020-06-10 |
| Royalty Pharma–AiCuris: letermovir, 202006 acquisition of partial royalty interest on letermovir for one-time payment of $220m by Royalty Pharma |
2020-06-09 |
| Atlas Venture–SEVERAL: investment, 202006 closing of $400m Fund XII |
2020-06-05 |
| Tropic Biosciences–SEVERAL: investment, 202006 financing round Series B $28.5m led by Temasek |
2020-06-04 |
| Tropic Biosciences–Temasek: investment, 202006 financing round Series B totalling $28.5m incl new + lead investor Temasek |
2020-06-04 |
| NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures |
2020-06-03 |
| Prilenia–Genworks 2: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Genworks 2 |
2020-06-03 |
| Prilenia–Sectoral Asset Management: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Sectoral Asset Management |
2020-06-03 |
| Prilenia–SEVERAL: investment, 202006 financing round Series A $62.5m led by new investor Forbion |
2020-06-03 |
| Prilenia–Talisman Capital Partners: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Talisman Capital Partners |
2020-06-03 |
| Twist Bioscience–SEVERAL: investment, 202006 public offering $100m+$15m with 3m+455k shares common stock at $33/share |
2020-06-03 |
| Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility |
2020-05-27 |
| Argenx–SEVERAL: investment, 202005 global offering $862.5 via ADS offering in US + private placement in Europe |
2020-05-26 |
| Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital |
2020-05-26 |
| Themis Bioscience–Merck (US): investment, 202005– acquisition €na all remaing shares of Themis via Merck subsidiary |
2020-05-26 |
| Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications |
2020-05-25 |
| Stratos–Roche: investment, 202005 acquisition €na of Stratos Genomics by Roche |
2020-05-22 |
| GSK–Samsung: biologicals contract manufacturing, 202005–2028 supply up to $231m of Benlysta + other biologics by Samsung Biologics |
2020-05-21 |
| HotSpot Therapeutics–Atlas Venture: investment, 202005 financing round Series B totalling $65m incl existing + co-investor Atlas Venture |
2020-05-21 |
| HotSpot Therapeutics–EMS (BR): investment, 202005 financing round Series B totalling $65m incl co-investor Cleva Pharma |
2020-05-21 |
| HotSpot Therapeutics–GSK: investment, 202005 financing round Series B totalling $65m incl lead investor SR One |
2020-05-21 |
| HotSpot Therapeutics–Merck (US): investment, 202005 financing round Series B totalling $65m incl co-investor MRL Ventures Fund |
2020-05-21 |
| HotSpot Therapeutics–SEVERAL: investment, 202005 financing round Series B $65m led by SR One |
2020-05-21 |
| HotSpot Therapeutics–Sofinnova: investment, 202005 financing round Series B totalling $65m incl existing + co-investor Sofinnova Partners |
2020-05-21 |
| HotSpot Therapeutics–Solasta Ventures: investment, 202005 financing round Series B totalling $65m incl co-investor Solasta Ventures |
2020-05-21 |
| HotSpot Therapeutics–Tekla Capital: investment, 202005 financing round Series B totalling $65m incl co-investor Tekla Capital Management |
2020-05-21 |
| HotSpot Therapeutics–Verge Scientific Communications: public relations, 202005 service existent by Verge |
2020-05-21 |
| Moderna–Morgan Stanley: financial services, 202005 supply service Morgan Stanley is sole book-running manager for up $1.54b public offering |
2020-05-21 |
| Nautilus Biotechnology–Walker Communications: public relations, 202005 service existent by Walker Communications |
2020-05-21 |
| Octant–8VC: investment, 202005 financing round Series A totalling $30m incl co-investor 8VC |
2020-05-20 |
| Octant–Allen & Co: investment, 202005 financing round Series A totalling $30m incl co-investor Allen & Co |
2020-05-20 |
| Octant–Andreessen Horowitz: investment, 202005 financing round Series A totalling $30m incl lead investor Andreessen Horowitz |
2020-05-20 |
| Octant–SEVERAL: investment, 202005 financing round Series A $30m led by Andreessen Horowitz |
2020-05-20 |
| Octant–SV Angel: investment, 202005 financing round Series A totalling $30m incl co-investor SV Angel |
2020-05-20 |
| Idorsia–SEVERAL: investment, 202005 capital increase CHF330m offering of 11m new shares at CHF30/share to qualified investors |
2020-05-19 |
| Phlow–United States (govt): grant, 202005– BARDA contract $354m for 4y plus optional $458m to secure domestic drug production in US |
2020-05-19 |
| Holmusk–Health Catalyst Capital: investment, 202005 financing round Series A totalling $21.5m incl co-lead investor Health Catalyst Capital |
2020-05-18 |
| Holmusk–Heritas Capital: investment, 202005 financing round Series A totalling $21.5m incl existing + co-investor Heritas Capital |
2020-05-18 |
| Holmusk–SEVERAL: investment, 202005 financing round Series A $21.5m co-led by Optum Ventures + Health Catalayst Capital |
2020-05-18 |
| Holmusk–UnitedHealth: investment, 202005 financing round Series A totalling $21.5m incl co-lead investor Optum Ventures |
2020-05-18 |
| Moderna–SEVERAL: investment, 202005 public offering $1.34b+$200.6m with 17.6m+2.64m shares common stock at $76/share |
2020-05-18 |
| Nautilus Biotechnology–Allen Group: investment, 202005 financing round Series B totalling $76m incl new + lead investor Vulcan Capital |
2020-05-18 |
| Nautilus Biotechnology–AME Cloud Ventures: investment, 202005 financing round Series B totalling $76m incl existing + co-investor AME Cloud Ventures |
2020-05-18 |
| Nautilus Biotechnology–Andreessen Horowitz: investment, 202005 financing round Series B totalling $76m incl existing + co-investor Andreessen Horowitz |
2020-05-18 |
| Nautilus Biotechnology–Bezos Group: investment, 202005 financing round Series B totalling $76m incl new + co-investor Bezos Expeditions |
2020-05-18 |
| Nautilus Biotechnology–Bolt: investment, 202005 financing round Series B totalling $76m incl existing + co-investor Bolt |
2020-05-18 |
| Nautilus Biotechnology–Defy Partners: investment, 202005 financing round Series B totalling $76m incl new + co-investor Defy Partners |
2020-05-18 |
| Nautilus Biotechnology–Madrona Venture: investment, 202005 financing round Series B totalling $76m incl existing + co-investor Madrona Venture Group |
2020-05-18 |
| Nautilus Biotechnology–Perceptive Advisors: investment, 202005 financing round Series B totalling $76m incl new + co-investor Perceptive Advisors |
2020-05-18 |
| Nautilus Biotechnology–SEVERAL: investment, 202005 financing round Series B $76m led by Vulcan Capital |
2020-05-18 |
| Calliditas Therapeutics–SEVERAL: investment, 202005– filing of US IPO of ADSs at Nasdaq Global Market |
2020-05-14 |
| Calliditas Therapeutics–SEVERAL: investment, 202005– private placement outside US announced concurrent filing of US IPO of ADSs |
2020-05-14 |
| Immunai–SEVERAL: investment, 202005 seed financing round $20m co-led by Viola Ventures + TLV Partners announced at emergence from stealth |
2020-05-14 |
| Immunai–TLV Partners: investment, 202005 seed financing round totalling $20m incl co-lead investor TLV Partners |
2020-05-14 |
| Immunai–Viola Ventures: investment, 202005 seed financing round totalling $20m incl co-lead investor Viola Ventures |
2020-05-14 |
| Optibrium–OpenEye Scientific: cheminformatics, 202005– collab product integration OE libraries + toolkits with StarDrop software |
2020-05-12 |
| Bluebird Bio–Hitachi: contract manufacturing, 202005– supply expansion long-term developm + manufacturing by HCATS + Apceth for gene therapies |
2020-05-11 |
| Novartis–Dyno Therapeutics: gene therapy, 202005– collab design of AVV vectors for ophthalmic gene therapies using AI-based CapsidMap platform |
2020-05-11 |
| Oncopeptides–SEVERAL: investment, 202005 directed share issue SEK1.414b ($144m) with 12.295m new shares at SEK115/share |
2020-05-05 |
| Stemline Therapeutics–Menarini: investment, 202005– acquisition up to $677m ANNOUNCED |
2020-05-04 |
| ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m |
2020-05-01 |
| Moderna–Lonza: biologicals contract manufacturing, 202005–203004 collab strategic 10y manufacture of mRNA1273 vaccine + other Moderna products |
2020-05-01 |
| Lyra Therapeutics–SEVERAL: investment, 202004–202005 IPO $56m+$8.4m with 3.5m+525k shares commonc stock at $16/share at Nasdaq Global Market |
2020-04-30 |
| Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties |
2020-04-30 |
| Polyplus-transfection–Warburg Pincus: investment, 202004 investment resulting in Warburg Pincus + ArchiMed owning equal shares + voting rights |
2020-04-29 |
| Robocath–SEVERAL: investment, 202004 financing round Series C €40m led by MicroPort Scientific |
2020-04-29 |
| Taysha Gene Therapies–SEVERAL: investment, 202004 seed financing round $30m co-led by PBM Capital + Nolan Capital |
2020-04-29 |
| Compass Pathways–ATAI Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor ATAI Life Sciences |
2020-04-27 |
| Compass Pathways–Otsuka: investment, 202004 financing round Series B totalling $80m incl new investor MSRD |
2020-04-27 |
| Compass Pathways–Perceptive Advisors: investment, 202004 financing round Series B totalling $80m incl new investor Perceptive Advisors |
2020-04-27 |
| Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors |
2020-04-27 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
